Grok

Grok is no longer just a chatbot—it's becoming the brain of X. The coming integration into X's core recommendation algorithm marks a decisive step from conversation to curation, pitting it directly against Claude 3, Gemini 3 Deep Think, and GPT-5. Meanwhile, xAI is hedging on domain-specific training: hiring Wall Street lenders for high-finance data and already seeing Grok used in a non-biologist's design of an mRNA cancer vaccine for a dog. This push into biotech and finance, combined with its reliance on recursive intelligence growth, suggests xAI is engineering broad applicability rather than single-benchmark dominance. Yet the graph data shows only 3 mentions in 30 days—low visibility for a model aiming to displace incumbents. The question: can Grok convert niche use cases into market share before its deeper-pocketed rivals lock in their ecosystems?

• ·Grok to integrate into X's core recommendation algorithm next week, leveraging real-time data.
• ·Competes head-to-head with GPT-5, Claude 3, and Gemini 3 Deep Think.
• ·Trained on high-level finance via Wall Street hires; used for custom mRNA vaccine design.
• ·Relies on recursive intelligence growth technology for self-improvement.
• ·Recent mention volume is low (3 in 30 days), raising adoption risk.